Avella Newsroom

January 1, 1970|
Supporting Continuity of Care for High-Risk Patients
June 12, 2020| CATEGORIES: Specialty Pharmacy , Press Feature
The ongoing challenges of the coronavirus disease 2019 (COVID-19) pandemic are disproportionally affecting specialty patients with chronic medical conditions, including high-risk populations such as the elderly and immune-compromised. Patients taking a specialty drug often rely on enhanced clinical services to ensure safe use of the drug and optimize therapeutic outcomes.
Going Beyond the Prescription in Specialty Pharmacy
March 19, 2019| CATEGORIES: Specialty Pharmacy , Press Feature

Michael Zeglinski, RPh, Senior Vice President of Specialty Pharmacy OptumRx, Chief Executive Officer at Avella and BriovaRx Specialty Pharmacies recently penned this article in Specialty Pharmacy Times about ways the health system can be optimized for patient care. 

Avella's Eric Sredzinski Named Finalist for Phoenix Business Journal's Health Care Heroes Award
August 27, 2018| CATEGORIES: Avella , Specialty Pharmacy , Press Feature

Thursday, August 23rd 2018 - Avella EVP of Clinical and Quality Assurance, Eric Sredzinski, was named a finalist for the Phoenix Business Journal Health Care Heroes Awards in the Non-Physician category. 

As an executive vice president at Avella Specialty Pharmacy, Eric Sredzinski is responsible for the development and oversight of all clinical programs and services provided by Avella.

Specialty Pharmacy Feeling the Strain as Financial Needs Increase
August 13, 2018| CATEGORIES: Specialty Pharmacy , Press Mention

Avella EVP of Clinical and Quality Assurance, Eric Sredzinski, was recently quoted in the following Specialty Pharmacy Continuum article.

A perfect storm is brewing as specialty drug prices reach all-time highs, out-of-pocket drug costs increase and financial assistance programs reach capacity.

“While commercial and Medicare Part D patients are seeing rising cost-sharing requirements and greater demand for assistance, the increasing contributions from drug companies over the past five years seem to be plateauing,” Daniel Klein, the president and CEO of the Patient Access Network (PAN) Foundation, said during the Asembia 2018 Specialty Pharmacy Summit.

Limiting the Distribution of Oncology Drugs
July 23, 2018| CATEGORIES: Specialty Pharmacy , Oncology , limited distribution drugs

The following article was written by Avella's EVP of Clinical & Quality Assurance, Eric Sredzinski, and published in Specialty Pharmacy Times.

Oncology is already among the top therapeutic classes in specialty pharmacy.1 Experts say that drugs to fight cancer will continue to dominate the next wave of FDA approvals and enter the market at a rapid pace. Yet specifically how these medications are delivered to patients is also expected to evolve over time. This is especially true as manufacturers look to partner with specialty pharmacies that possess highly specific expertise in supporting patients with cancer and their complex treatment regimens.

Avella Releases New Report on Anticipated Specialty Drug Approvals
April 27, 2018| CATEGORIES: Specialty Pharmacy , Press Release , limited distribution drugs

The leading specialty pharmacy has compiled insights about the specialty drug pipeline along with an analysis of the network distribution strategies for these medications.

Phoenix, AZ -- Avella has just announced the release of a 16-page report detailing the specialty drug pipeline, including all of the latest medications expected to receive FDA approval within the coming months. The 2018 Q2 Specialty Medication Pipeline Report provides at-a-glance information about all of these therapies including indications, approval status, anticipated costs, clinical considerations and therapeutic alternatives, among other key data points. It also provides helpful explanations of the various designations and approval processes undertaken by the FDA for specific types of medication such as orphan drugs and breakthrough therapies.

NCPDP Annual Conference Keynote Panel to Address “Data Challenges and Opportunities to Improve the Patient Journey”
April 17, 2018| CATEGORIES: Avella , Specialty Pharmacy , Press Mention

NCPDP announced today the Opening Keynote Panel for its 2018 Annual Technology & Business Conference, Industry United to Improve the Patient Journey, May 7-9, 2018, at the Westin Kierland Resort & Spa in Scottsdale, Arizona. The Keynote Panel will address “Data Challenges and Opportunities to Improve the Patient Journey,” on Tuesday, May 8, 2018. Avella founder and chairman of the board, John Musil, will participate on the panel representing specialty pharmacy.

LD Networks Shrinking; What Do You Need to Get In?
April 2, 2018| CATEGORIES: Specialty Pharmacy , Press Feature , limited distribution drugs

Many of today’s most effective specialty drugs are distributed through limited networks of specialty pharmacies, ranging in size from exclusive (one to two pharmacies) through limited small (two to five pharmacies) and limited large (six to 15 pharmacies). A new white paper from Avella Specialty Pharmacy reports that with 79.2% of manufacturers managing their specialty products through a limited distribution (LD) model, these LDs are shrinking even more, consisting of fewer pharmacies than they did just a decade ago.

Part Two: Influential Women in Specialty Pharmacy Help Guide the Industry
September 26, 2017| CATEGORIES: Specialty Pharmacy , Press Mention

If you haven’t already, we hope you’ll begin reading this 2-part series by viewing part 1, where we profile 5 women who we’ve identified among specialty pharmacy’s most highly-regarded leaders. In the conclusion to this series, you’ll meet another group of women who are applying their unique capabilities and expertise to positively impact their organizations, as well as the industry at large.

Avella Tops 2016 List of Fastest-Growing, Private Specialty Pharmacies
September 7, 2017| CATEGORIES: Specialty Pharmacy , Press Mention

This article originally appeared on Drug Channels

Time for our annual review of the latest Inc. 5000 list, the magazine’s annual ranking of the fastest-growing private companies in the United States. The list offers a valuable snapshot of the dynamic specialty pharmacy industry. This marks our sixth annual review of the list.

We have identified 15 specialty pharmacies on the 2017 list, which is based upon revenue growth from 2013 to 2016. Annual revenues range from $6.4 million to $1.3 billion.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.